Scrutinizing Primary Endpoints in ALS Clinical Trials: ALSFRS-R, Survival or a Composite?
Speaker
Prof. dr. Leonard van den Berg
Neurologist
Prof. dr. Leonard van den Berg is a neurologist at University Medical Centre (UMC) Utrecht and ALS Centrum. He is experienced in conducting global ALS trials, established the prominent TRICALS site network, and is chair of the European Network for the Cure of ALS.
During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.
They touched upon:
- Primary endpoints in ALS clinical trials
- Regulatory requirements: differences between EMA and FDA
- Statistical considerations for ALSFRS-R, survival and composites
Followed by a Q&A session.
Speakers: Prof. Leonard van den Berg, MD, PhD & Dr. Ruben van Eijk, MD, PhD
Related webinars
Webinar – Boosting patient enrolment and retention in clinical trials: Expert Insights & Tips
On June 30, at 16.00 CEST, we will present the webinar: Boosting patient enrolment and retention in clinical trials: Expert Insights & TipsJoin us for an interactive discussion with experts who will draw upon recent cardiology and neurolog...
Webinar – The role of EEG in dementia trials
On May 6th, 2025, we will organised the webinar: The role of EEG in dementia trials During this webinar, our speakers Pieter van Mierlo, Dr. Willem de Haan and host Lieza Exalto will explore the following topics:Practical aspects and resti...
Webinar – Time to event trial designs in ALS: How useful are they?
On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
